Methimazole vs Propylthiouracil for Hyperthyroidism: How to Choose

Methimazole is first-line for most adults with hyperthyroidism due to better safety and once-daily dosing. PTU is preferred in the first trimester of pregnancy and in thyroid storm. Both require monitoring for liver dysfunction and the rare complication of agranulocytosis.

How methimazole and PTU actually work

Both methimazole and propylthiouracil (PTU) belong to the thionamide family of antithyroid drugs. Their primary action is the same: they inhibit thyroid peroxidase (TPO), the enzyme inside the thyroid gland that links iodine to tyrosine residues on thyroglobulin to produce T4 and T3. With TPO blocked, the gland makes less new hormone within days, though circulating T4 and T3 already in the bloodstream take weeks to clear — which is why patients usually don't feel substantially better for 4 to 8 weeks [C1][C3].

PTU has one extra mechanism that methimazole lacks: in peripheral tissues, it inhibits type 1 deiodinase, the enzyme that converts the inactive T4 into the active T3. This is clinically meaningful only in a few settings — most importantly thyroid storm, where the goal is to crash T3 levels as fast as possible [C1][C2]. In routine outpatient hyperthyroidism, this added effect doesn't translate into better outcomes; methimazole alone controls the disease at lower doses with less toxicity [C1][C6].

Methimazole is roughly 10 times more potent than PTU on a milligram basis, has a longer half-life (about 6 hours vs 1.5 hours), and concentrates inside the thyroid gland, which is why it can be dosed once daily once the patient is stable. PTU usually needs to be split into 2 or 3 doses per day to maintain steady inhibition [C1][C3].

How effective each one is

Head-to-head, methimazole reaches euthyroidism (normal hormone levels) faster and at lower doses than PTU, and is more durable across the maintenance phase. A randomized trial in Graves' disease found methimazole and PTU both improved thyroid function effectively, but methimazole produced more consistent biochemical control with fewer dose adjustments [C6]. Larger reviews confirm methimazole as the preferred first-line antithyroid drug in non-pregnant adults, with remission rates after 12 to 18 months of treatment in the 30 to 50 percent range — comparable on either drug, but achieved with less burden on methimazole [C1][C4].

For long-term low-dose therapy (continuing methimazole for several years rather than escalating to radioactive iodine or surgery), the evidence has grown over the last decade: extended courses appear to maintain remission in a meaningful subset of Graves' patients without obvious accumulating risk, and your endocrinologist will weigh this against definitive therapy on an individual basis [C4].

When PTU is the right choice

There are three specific situations where PTU is preferred over methimazole [C1][C2][C5]:

1. First trimester of pregnancy. Methimazole exposure during weeks 6 to 10 of gestation is associated with a specific cluster of birth defects (aplasia cutis of the scalp, choanal atresia, esophageal atresia, omphalocele). Recent real-world cohort data continue to support switching to PTU before conception or as soon as pregnancy is confirmed, and switching back to methimazole at the start of the second trimester, when PTU's liver-injury risk outweighs the residual teratogenic concern [C5][C7].
2. Thyroid storm. The added block on peripheral T4-to-T3 conversion gives PTU a theoretical edge in this medical emergency, where the goal is to drop active T3 as fast as possible [C1][C2]. See thyroid-storm-emergency.
3. Methimazole intolerance (rash, GI upset, mild liver enzyme elevation) — PTU can be a fallback, recognizing that allergic cross-reactivity occurs in roughly half of patients.

Side effects and monitoring

Both drugs share a class profile of minor reactions — rash, itching, joint pain, mild GI upset, and transient liver enzyme elevation — in roughly 5 percent of patients. The differences live at the serious end of the spectrum [C1][C3]:

• Agranulocytosis (a sudden drop in neutrophils below 500/microliter, leaving the patient defenseless against bacterial infection) occurs in roughly 0.2 to 0.5 percent of patients on either drug. It is dose-dependent for methimazole and idiosyncratic for PTU. Any fever or sore throat in the first 90 days of either drug warrants an immediate CBC — patients should be instructed to stop the drug and call their endocrinologist [C1][C3][C8].
• Severe hepatotoxicity is the signature concern with PTU. PTU has been associated with rare but fatal liver failure, particularly in children. The FDA carries a boxed warning. Methimazole's liver injury, when it occurs, is more typically cholestatic and tends to resolve on drug discontinuation [C1][C2].
• ANCA-positive vasculitis is a rare delayed complication of PTU after months to years of use.

Baseline labs before starting either drug typically include a CBC with differential and liver enzymes (ALT, AST, alkaline phosphatase, bilirubin), repeated if symptoms develop. Routine surveillance CBCs in asymptomatic patients have a low yield and are not universally recommended; symptom-triggered checking is the standard [C1].

What does NOT help

• "Natural" antithyroid herbs (bugleweed, lemon balm, motherwort) have minimal trial data and are not a substitute for thionamides in confirmed hyperthyroidism [C8].
• Low-iodine diets don't replace antithyroid drugs in Graves' disease; iodine restriction can briefly help in iodine-induced thyrotoxicosis but is not a long-term strategy [C1].
• Switching drugs to "give the liver a rest" in a stable patient with normal LFTs has no evidence and risks losing control of the disease.
• Stopping the drug at the first sign of fatigue or hair changes — these usually reflect the transition through normal hormone levels, not a drug failure. Your endocrinologist will adjust dose, not discontinue [C1][C4].

Practical guidelines

1. Methimazole is the default starting drug for any non-pregnant adult with confirmed hyperthyroidism. Typical starting dose: 10 to 20 mg per day, once daily [C1][C2].
2. Switch to PTU before conception, or immediately at the first positive pregnancy test, and switch back to methimazole at the start of the second trimester. Your endocrinologist will manage the timing [C5][C7].
3. Know the agranulocytosis red flags. Fever, sore throat, mouth ulcers, or any sudden infection in the first 3 months warrants stopping the drug and getting a same-day CBC [C1][C3].
4. Baseline CBC and LFTs before starting either drug, and again with any concerning symptom — not on a routine schedule [C1].
5. Stay on the drug long enough for a fair trial. Most antithyroid courses last 12 to 18 months before remission is assessed; stopping early dramatically lowers remission rates [C1][C4].
6. Tell every prescriber you take an antithyroid drug — particularly before any surgery, iodinated contrast scan, or new medication.

Frequently asked questions

Is PTU stronger than methimazole? No — methimazole is roughly 10 times more potent per milligram and provides more consistent control. PTU's "extra" mechanism (blocking T4-to-T3 conversion) only matters in thyroid storm [C1][C2].

Will methimazole cure my hyperthyroidism? Antithyroid drugs control hyperthyroidism but do not cure the underlying autoimmune process in Graves' disease. About 30 to 50 percent of patients achieve sustained remission after 12 to 18 months; others relapse and may need radioactive iodine or surgery [C1][C4].

Can I get pregnant on methimazole? Plan with your endocrinologist. Methimazole should be switched to PTU before conception or at the first positive pregnancy test because of first-trimester teratogenic risk; you'll switch back at the start of the second trimester [C5][C7]. See thyroid-pregnancy-fertility.

How often will my labs be checked? Typically every 4 to 6 weeks during the dose-finding phase, then every 2 to 3 months on a stable maintenance dose. CBC and LFTs are only repeated routinely if symptoms develop [C1].

What if I get a rash? Mild rash can sometimes be managed with antihistamines without stopping the drug; persistent rash, fever, or any swelling needs urgent contact with your endocrinologist. About half of patients allergic to one thionamide will tolerate the other [C1][C3].

Bottom line

Methimazole is first-line for most adults with hyperthyroidism — lower doses, once-daily dosing, better safety profile, and equal or better long-term control than PTU [C1][C2][C6]. PTU has a specific role in the first trimester of pregnancy and in thyroid storm, but otherwise carries a higher risk of severe liver injury and ANCA-vasculitis [C1][C5][C7]. Both share a small but serious risk of agranulocytosis — fever or sore throat in the first 90 days is a red flag, not a cold [C1][C3]. Stay on the drug long enough for a fair trial, monitor with your endocrinologist, and treat the choice between drugs as situational, not preferential [C4][C8].